New Exosome-Based COVID booster enters human testing

NCT ID NCT07095231

Completed ⭐️ VACCINE ⭐️ Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new COVID-19 booster vaccine, STX-S, in 60 healthy adults who had already received a primary vaccine series and at least one booster. The vaccine uses tiny particles called exosomes to deliver spike proteins. The main goal was to check safety and side effects at three different doses, while also measuring immune responses in the blood and nose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: STX-S (an experimental vaccine using exosomes to deliver spike proteins)
What this could lead to: If successful, this could lead to a new type of COVID-19 booster that may offer better or longer-lasting protection.
What could go wrong: This is a very early Phase 1 trial with only 60 people, so safety and immune response are still unknown. It may not work as hoped or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Coronavinae infectious disease COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

Kaiser Permanente Washington Health Research Institute

Seattle, Washington, 98101-1466, United States
The University of Washington - Virology Research Clinic

Seattle, Washington, 98104, United States
University of Rochester Medical Center - Vaccine Research Unit

Rochester, New York, 14642-0001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.